This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for RadiationOncology (ASTRO) meeting.
milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for RadiationOncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for RadiationOncology ( ASTRO ). Ensure patients and radiation oncologists make care decisions, not insurance companies.
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiationoncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.
Ultrasound model predicts liver disease progression. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. SPECT/CT reveals heart’s response to tafamidis.
milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiationoncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of RadiationOncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,
Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content